Sotatercept denied for missing prior authorization by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for sotatercept are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Requires Prior Authorization for Sotatercept

Sotatercept is a specialty biologic for pulmonary arterial hypertension (PAH) that UHC places in its prior authorization (PA) program, meaning coverage requires advance clinical review before the drug is dispensed. A prior-auth denial is not a final decision — it is the first step in a structured process that is entirely worth pursuing. Most PA denials for sotatercept are overturned at appeal when the complete clinical picture is submitted.

PA denials commonly occur because the initial submission was incomplete, did not document the required prior therapies, did not include specialist confirmation, or was submitted using the wrong diagnosis code. None of these are reasons to stop.

## Your Appeal Rights

• Peer-to-peer review: Before filing a formal appeal, the prescribing physician can request a peer-to-peer call with UHC's medical reviewer. This is often the fastest route to reversal and should be the first step if time allows.
• Internal appeal (ERISA §503 / ACA §2719): If peer-to-peer fails or is not available, file a written internal appeal with full supporting documentation. UHC must provide a full-and-fair review.
• External independent review: After internal appeal denial, you may request review by an independent IRO. External reviewers apply clinical standards, not the plan's internal PA criteria. File within the deadline on your Explanation of Benefits — typically approximately four months from denial.
• Expedited review: PAH's progressive, potentially life-threatening nature typically qualifies for expedited review. Submit the request in writing and note the clinical urgency.

## Documentation to Gather

1. Diagnosis confirmation: Right-heart catheterization report, specialist diagnosis notes, echocardiography, and any relevant imaging confirming PAH classification. 2. Functional class and severity: Objective functional assessments (e.g., 6-minute walk distance) and clinical notes describing disease burden. 3. Prior therapy history: Dated records showing which PAH therapies have been tried, for how long, and the clinical outcome or reason for inadequacy. 4. Specialist involvement: Documentation that a board-certified specialist (pulmonology or PAH center) is managing the patient's care. 5. Prescriber medical-necessity letter: A detailed letter tying the clinical record to each of UHC's stated PA criteria.

## Criteria-Mapping Structure

Obtain UHC's published prior authorization criteria for sotatercept from their website or by requesting them directly. Copy each stated requirement into a document. For each requirement, write the exact chart fact that satisfies it — test name, date, and result. Submit this mapping alongside the appeal. Explicit criterion-by-criterion documentation dramatically increases reversal rates at both internal and external review.